Evidence map›Paper›PMID 39627959›Full record

ArticleAmerican journal of hematology2025

Feasibility of a Biomarker-Based Screening for Pre-Symptomatic AL Amyloidosis in Patients With Intermediate/High-Risk MGUS.

Silvia Mangiacavalli, Paolo Milani, Claudio Salvatore Cartia, Marzia Varettoni, Michele Palumbo, Marco Basset, Valeria Masoni, Mario Nuvolone, Andrea Foli, Virginia Valeria Ferretti and 3 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Silvia MangiacavalliDivision of Hematology, Fondazione IRCCS Policlinico san Matteo, Pavia, Italy.ORCID 0000-0001-9787-3083
Paolo MilaniDepartment of Molecular Medicine, University of Pavia, Italy.
Claudio Salvatore CartiaDivision of Hematology, Fondazione IRCCS Policlinico san Matteo, Pavia, Italy.
Marzia VarettoniDivision of Hematology, Fondazione IRCCS Policlinico san Matteo, Pavia, Italy.ORCID 0000-0001-7304-1629
Michele PalumboDepartment of Molecular Medicine, University of Pavia, Italy.
Marco BassetAmyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico san Matteo, Pavia, Italy.
Valeria MasoniDepartment of Molecular Medicine, University of Pavia, Italy.
Mario NuvoloneDepartment of Molecular Medicine, University of Pavia, Italy.ORCID 0000-0001-8334-1684
Andrea FoliAmyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico san Matteo, Pavia, Italy.
Virginia Valeria FerrettiBiostatistics and Clinical Trial Center, Fondazione IRCCS Policlinico san Matteo, Pavia, Italy.
Giampaolo MerliniDepartment of Molecular Medicine, University of Pavia, Italy.
Luca ArcainiDivision of Hematology, Fondazione IRCCS Policlinico san Matteo, Pavia, Italy.ORCID 0000-0002-9504-991X
Giovanni PalladiniDepartment of Molecular Medicine, University of Pavia, Italy.

Funding

Accelerator Award ProgramAssociazione Italiana per la Ricerca sul CancroCancer Research UK 4013 C355/A26819European Union-Next Generation EU-PNRR M6C2-Investment 2.1 'Valorizzazione e potenziamento della ricerca biomedica del SSN' PNRR-MR1-2022-12376853Fondazione Cariplo '2018-0257'Italian Ministry of Health, Ricerca Finalizzata GR-2018-12368387Italian Ministry of Research and Education PRIN 20207XLJB2the Telethon Foundation GJC23044
6 · The paper itself

Abstract

Biomarker-based screening enables early detection of AL amyloidosis in intermediate/high-risk MGUS patients. Our study shows that identifying pre-symptomatic AL through biomarker longitudinal monitoring allows early treatment, leading to significant organ function recovery.

Indexed as

BiomarkersFeasibility StudiesImmunoglobulin Light-chain AmyloidosisMonoclonal Gammopathy of Undetermined SignificanceAgedFemaleHumansMaleMiddle AgedBiomarkersAL amyloidosisbiomarkersMGUSscreening

Identifiers

PMID39627959
PMCPMC11705207

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.